Skip to main content
TRAX $44.39 -0.25%
TRAX logo
TRAX · First Tracks Biotherapeutics, Inc.
Track TRAX — free
$44.39 -0.11 (-0.25%)
Market Cap
$1.87B
Shares
42.02M
Volume · Nov 19 115.8K Avg daily vol (3M) 827.63K
All webcasts

Conference · 2026-11-10

First Tracks Biotherapeutics, Inc. (TRAX) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay
Nov 10, 2026 28:20 37 turns
Period
2026-11-10
Runtime
28:20
Sources
2 artifacts

Transcript & audio

28:20 Audio

Welcome to Google and I am third annual Healthcare Innovation Conference. My name is Yatin Suneja. It is my pleasure to welcome our next presenting company, First Tracks from the company. We have the CEO, Dan Feka. Dan, why don't you maybe make some opening comments, give us some highlights. I mean, it's been a very, very productive year for you this year, but just orient our investors on not only the key molecule that you have, which is the CD122, but talk a little bit about the pipeline, and then I'll go into the The Q&A.

Dan Figa CEO

All right. Good morning, everyone. Good afternoon, wherever we are. You know, it's exciting. So it's year one for first tracks. We came in with a running start off our spin from Anaptis, and I agree with you. I think we've, sitting here a day in November, and off of our recent celiac data for our CD122 antagonists that we announced last month, we couldn't have had a better result. And I think that we have a potential best-in-class program. The data exceeded ours and I think others' expectations with what we delivered in celiac showing both a profound benefit on histology and symptoms in terms of preventing celiac worsening. And we have a very ambitious plan in store for this program that we've outlined that's ongoing today and what we've previewed for 2027. A year from now, we will be in four indications being developed in at least two therapeutic areas for this drug. We'll be moving to late-stage trials for celiac disease and hopefully have released equally positive data in EOE. So that's just for the lead. Right out of the gate, we had three clinical stage assets that we started the company with, including Rosnilmab, a PD-1 depleter, and AMB-101, which is a BDCA2 targeting agent. It's a depleter of plasmacytoidendritic cells. So three development stage programs. We still have our research engine in the company, and we are well-funded with over $350 million of cash sitting here today. So ambitious plans and a lot going on in the business.

Well, very good. Thank you for that. So let's start with the CD122 molecule. First, just specifically on the molecule. To us, it looks differentiated. You have a different modality that you are offering for formulation that you're offering and maybe the potency. So can you just talk about just purely how the asset looks when you do experiment in your preclinical data? Sure.

Dan Figa CEO

So it is an antagonist of CD122, which presents in a receptor complex, either dimeric or trimeric receptor complex, on various types of immune cells. And that's important because it offers a We'll see you next time. This is a multi-modal, almost multi-targeting agent. We often refer back to blocking IL-15 signaling. There are other IL-15-only targeting cytokine antagonists that exist that we are compared to, but we also importantly block IL-2 signaling. This is relevant in the diseases that I've already mentioned, but in celiac specifically, IL-2 is a cytokine that is released from CD4 cells when the byproduct of gluten is presented by APCs. CD4s get activated and release IL-2 immediately upon within an hour of gluten exposure. So there's just really important proof of principle why the dual-signal blocking just in that disease alone provides a lot of value. You're asking about preclinical data. We've shown, I think, difference in potency from both the IL-15s as well as other CD122 programs on a reduction on the various cytokines as well as CD4 T-cells and CD8 T-cells in various preclinical in vitro assays. And I think also, you know, again, head-to-head in different animal models as it relates to celiac disease or EOE. So I think we've shown the potency differentiation of a high affinity blocking both different cytokine signaling and then different immunology pathways, both Th1 and CD8. I think there's a breadth of data that we've demonstrated. I think importantly, at least for today, we are subcutaneously administered. I think that gives us administration advantage out of the gate in the ongoing trials relative to competition. I think then finally, and we'll talk more about this, I think our clinical data, at least from what we're aware of today, looks differentiated. So all continues to add up and build on prior data sets that have been produced.

Yeah, and then maybe one more on high level. What is the development strategy? When I look at how you are disclosing the indication, you've been very careful and going after areas where I think the biology is a little bit more de-risk or less risk there. For example, like vitiligo, you only move forward after we have seen data in the space. So as the aperture sort of widen for this mechanism, how much risk are you willing to take? How should we think about indication expansion? It's not that you have enough, you have enough, but just talk about the strategy.

Dan Figa CEO

Well, I think we've been balanced and thoughtful on how we've done this. If you go back one year, when we were moving into patient-driven studies, we announced we were in celiac disease. We had a couple months, and then we announced we were moving to EOE. Now there was some proof of concept in a five-patient study of an IL-15 antagonist, not a CD122, where they showed EOS reduction in a symptomatic benefit in those five patients in an EOE trial. We did come out and say we're going to run a broader 50-patient EOE study in February of this year, so that's ongoing. But the reason I bring that up is that is not fully de-risked in the same way. I think we had more robust proof of concept in celiac disease. EOE has had plenty of challenges in development before with drugs that were being developed that, you know, And so the reason I'm bringing you back there is that I think there is meaningful risk in where we're going, but we are following the biology and our own preclinical data. We generate animal model data that showed we were flooring not just EOS in this aspergillus model in both the lung and the esophagus, But we're also flooring ILC2s, which are one of the immune cells that are deriving that disease, which we've seen being reduced with DUPI in that disease. So I think, you know, EOE, we're the only player right now between the IL-15s and CD122s that are in a clinical trial. So we took a leading role in EOE. In celiac, I think we filed thoughtfully, but we also came up with a trial design where we were doing not just a gluten challenge, but our upcoming data in Q1 of next year is what we're calling a healing study, and that's differentiated. So we were innovating there with trial design. You are correct that in vitiligo, we waited for proof of concept. We did see more risk there relative to celiac and EOE. We let folks de-risk there, and now we're just going to run straight into a Phase 2B trial and play catch-up, I think, now with a drug that potentially is differentiated. And the fourth indication, we've kept that in our pocket. You know, it's interesting. We announced we're going to UE, and then pops up on our competitors' websites, oh, we might be looking at UE. So there's a bit of a competitive dynamic. There's clearly preclinical drugs out of China that exist, and you look at some of the websites and material for them, And they're looking at celiac, EOE, and vitiligo, right? So I think there's going to be copycats in this space. So it just makes sense to announce where we're moving when we get there. And then we can decide once we announce the fourth indication how much risk or not you think there is based on data that exists clinically. That, you know, when we go announce what we're doing, we will have a fully supported preclinical package that we will present at that time.

Got it. Very good. So let's dive into the phase 1B cohort 1 data. Could you review the data for us? How does it stack versus the competition? Because now we have seen three programs producing data.

Dan Figa CEO

Sure. Let me walk through the trial design first, and we can talk about the results. So we ran a gluten challenge study that we read out last month. It was a 34-patient study, split one-to-one randomization of drug versus active. We enrolled patients that were greater than 2.0 on VHCD. And we treated them at baseline week two and week four with subcutaneous dosing, and then we gave a 14-day gluten challenge, and the gluten challenge was the equivalent of two slices of bread a day each day for those 14 days. So that was six grams of gluten a day. And then we read out the results based on a week six biopsy findings and another clinical workup. And what we observed was, I think, importantly, number one, we gave a very intense gluten challenge. And that was shown based on what was in the control arm, the findings in the control arm. So patients on placebo saw a 0.66 reduction on VHCD. On our active arm, we saw only a .17 reduction. So that was approximately .5 change in VHCD. That's best in class in terms of the delta. But I think even more importantly than that is a .17 decline is truly preventative. We reference a .25 decline as being clinically meaningful. That's based on consensus numbers from KOLs in the space. So we were under the clinical immune field detection of a change on VHCD. So that's really important given how much gluten we were giving. Patients with celiac disease aren't walking around eating two pieces of bread every single day for a couple of weeks. We're not saying we cured the disease, but that's a pretty profound result. That's complemented by what we saw in terms of the IEL impact. We saw a change of about 20, looking at IEL density. But I think more importantly, you know, again, and we're the only company to have shown this in intense gluten challenges, we actually saw a reduction from baseline on drug. Reduction in IELs. So giving gluten, IELs went down. That is not an expected finding. So then, so that's the histology. It's complemented by, I truly think, an upside surprise here on what we observed on symptomatic benefit. If you know someone with celiac disease and they... Eat a bite of bread. Forget two slices of bread. They'll be keeled over over time in various different ways. The PIRO that we were using our trial, the Selec disease severity or symptom diary, Selec disease symptom diary, it's measured daily, and you're measuring severity across five different symptoms. What we observed in this trial was a number of things. One, patients on drug did not see an increase across the entire tool, across any of these symptoms through that Gluten Challenge. So where they start at baseline, which was asymptomatic or very low basal levels of symptoms, did not increase through the 14-day Gluten Challenge. We saw a statistically significant difference then compared to what was observed on control on day one. We saw that on the total tool. We saw that with moderate and severe symptoms only. And that statistically significant difference was sustained through the first week on total symptoms and through the first 12 days on moderate and severe symptoms. That's even more profound when you couple with the fact that half of the patients in the control arm Actually took medicines to manage their symptoms, so the symptoms were observed, and then the patients in the control arm were taking drugs to manage them down. On the placebo arm, we had one patient that administered medicine in the trial. And so when you look at this in aggregate, Not only were we preventative of symptoms, we were STAT-SIG over a course of a trial, and you didn't have to take additional medicine. And then it was also just coupled with, I think, something that is an interesting anecdote. There's a major difference in the AEs that were reported. It was relatively benign AE reporting on the active arm versus the placebo arm. So that just is another way to look at the benefit we had. So we were preventative of disease on histology. We were preventative symptoms through the course of this gluten challenge. The data could have been better, and the drug was safe, tolerable. We had no dropouts in the study.

Got it, got it. So I want to go back on the point you make just now on how the absolute arm performed. Can you compare that with what we see with other agents? Because that's an important point, like the threshold of meaningfulness. I don't think we see that with our 15s. Just like maybe orient our investors on that.

Dan Figa CEO

So, look, I don't want to speak out of both sides of my mouth. Coming into the readout, we were counseling investors. It's hard to read across these studies. The gluten challenges are different across studies. We did 6 grams a day for 14 days. The Teva trial looked at 3 grams a day for a longer period of time. The Argenix trial looked at 8 grams a day for a small period of time, moving to 3 grams a day for a longer period of time. So they're all different. What we are pointing to here is, was the gluten challenge intense? I think, in fairness to the Teva results, they had a minus 0.88 on their control arm in terms of change in VHCD. They gave an intense gluten challenge. They saw a 0.4 delta. We saw something closer to a 0.5 delta. Is that a meaningful difference? Maybe. What I think is more important is what happened on the absolute arm in the TEVA trial. They had more than a 0.4 decline. That is above. The clinical meaningfulness. So while they were better than placebo, clearly, patients who took their drug did get worse and got worse more than what would be considered clinically meaningful, giving three grams of gluten a day. So I think there's a difference there that has to get impact in larger trials. None of these trials are huge. But I think if you're going to, if you'd rather have a... I think you'd rather have a result that you're protective of the clinical effect on the active arm. We're in a better position there. It is to be determined exactly what Teva saw with their IL-15 on prevention of symptoms. They have a pretty cloaked subjective line in their abstract that'll get presented at ICSD. So I think it's too premature to exactly comment on what they're seeing or not seeing on symptoms. I do feel that if they were STAT-SIG, they probably would have said it, but I think we have to wait and see what data is presented. And then similarly on the Energenics trial, I think in their press release, they saw statistical significance on VHCD. They didn't comment on symptoms. In an earnings report that they came out with a few weeks later, after we presented results, I think they did comment that in a pooled data set over a one-week period of time in a subset of symptoms, they started to see something. Again, that data needs to be presented, but these are subjective lines and press releases and hard to really react to.

Got it. Very good. Very helpful. I think this nuance on the performance of the active arm is, I think that's where I think a lot of investors are focusing on and understanding that nuance, which is good.

Dan Figa CEO

But here's what's important. Three different data sets, IL-15, CD122s, these classes or drugs, I think in aggregate, are having an effect on this disease. I love our data set itself on a small number of patients. I think that really should make, from the investor's sense, I know from the medical sense, we've talked to all the KOLs out there, there's actually traction in disease right now where nothing has worked over the last 20 years of drug development, and it seems like we're all collectively onto something here where we can make a pretty profound difference and ideally bring therapeutics to market where there's nothing today. I think at the highest level, that's what matters most right now. We all have drugs that work, and we're happy with our competitive positioning at FirstTracks.

Very good. So cohort two, that is a unique cohort in the sense that I think you are going to produce data, I think, the first in that type of patient population. What is that cohort? What are you trying to learn? What should we be expecting there?

Dan Figa CEO

Yeah, so let me just walk through what we're testing in the trial design really quickly first. So unlike the patients that we enrolled in the Gluten Challenge, they are greater than 2.0 on VHCD. The second cohort is looking at patients who are less than 2.5. So there is some overlap in there, but generally speaking, at least half these patients will be less than 2. So this is more considered severe mucosal injury or moderate and severe mucosal injury at baseline. These patients thought they were going to be enrolling in gluten challenge. They got biopsy results and observed. That they had injury where it would be unethical to give these patients more gluten, particularly if you were then in the one-to-one randomization of drug and placebo. If you were to get placebo, you weren't going to be giving those patients gluten. So instead, we enrolled them into a different study where we were observing over a three-month period of time, can we actually help these patients clear out the inflammation and make them better and recover the villi that has been destroyed by the attack from the gluten, From the inflammation from the gluten response. What we're doing in this study is we're similarly loading. We're doing a loading dose at baseline, week two, and week four subcutaneously, and then we're waiting eight weeks off drug. So I think this is really important. We are not a every-other-week therapy, generally speaking. We do have a loading dose, but here we are confident that we're giving enough drug to be above the IC-90 in tissue through and beyond 12 weeks. We're assessing and doing a biopsy at week 12 to assess, based on that severe or moderate severe injury at baseline, have we improved on VHCD? And have we reduced that baseline IEA level count at week 12 on the drug arm relative to placebo? Here's the unknown. We do not have a good understanding in the field how well patients who are not being administered gluten What is going to be their natural history of repair in that 12-week period of time? It's also not well documented when they had their exposure to gluten or multiple exposures to gluten that created or initiated that damage. Was it three months prior, six months prior? That's not known. So there is risk in this study where the control arm, the behavior and the control arm is unknown. What we're guiding investors to, here's our expectations, is we should see translational clearance of that inflammation. Reduction in IELs, we should see an impact on proliferation of CD4 T-cells, et cetera, and other cytokinectivity. That data won't be available at the top line, but we should see a numerical advantage on VHCD improvement and IEL reduction relative to control.

Got it.

Dan Figa CEO

And while we're not... Leaning into or changing our expectations on, and I'm explicitly not saying statistical significance. We don't know. We do feel more confident from our cohort one results that we can reduce IELs. And we saw reduction in IELs giving patients glue. We should see that on our drug. We should see an improvement on VHCD based on what we learned in cohort one as well. It's just the clinical meaningfulness of it at three months is an unknown. And you need six months to get to full repair availability. I versus three. So this is truly an experiment. It's aimed to de-risk a future trial and healing. We've seen from plenty of big pharmas a path forward, a registrational path forward in healing patients. And there's mapped out trials that have been done by Sanofi, Decada, Roche in much larger settings. This will help de-risk those studies. It's different than the learnings from cohort one, which brings us down a prevention path moving forward towards hopefully registration. So maybe there's two paths that we've now all collectively unlocked on prevention in addition to what we're assessing for healing in the second cohort that reads out in Q1 of this year.

Got it. Then would you, so because there is an overlapping, right, it's between 2 and 2.5, so would you give us a separate cut of the data for the guys who overlap between 2 and 2.5, or is just everybody sort of falls into the same?

Dan Figa CEO

Or are these patients just a little bit more severe, even though their relay ratio is 2.5?

The trial is not large enough to have a robust look.

Dan Figa CEO

It's not clear sitting here right now how many patients are going to be in each bucket as well, if it's going to be a meaningful data set across both arms. But I agree with you, there will be interesting case studies that will eventually be understood, at least internally of the company, of giving patients gluten in that moderate to severe range and different rates of healing or deterioration.

And are there I forgot the chain, I had a question, I forgot. So are there... Are there studies that we can reference to that are similar to this? Can we just go back and look at what do we expect?

Dan Figa CEO

The cohort two?

Yeah, cohort two.

Dan Figa CEO

No, there aren't. I think we're truly the first in the field doing this. There's a concept called siege in trials, where you're administering siege means simulated inadvertent gluten exposure, very low dose gluten. And the idea, so we gave six grams of gluten in our gluten challenge. Siege would be something like 0.1 to 0.3 grams intermittently. And the reason I'm bringing this up is the reason you do that is to mimic what happens in the world where there's exposure, right? You eat a crumb because it's mixed in with cooking somehow, right? And that's enough to instigate the immune reaction. It's important because there's something called the Hawthorne effect in a trial where a patient In a trial, if they went out to eat every couple weeks and they're careful with what they eat, well, maybe they don't go out to eat and they just hone in, right? And so you see improvement. We do not have that in this trial. This is natural exposure. Continue doing what you're doing. It does create risk in the control arm.

Got it. And how would the pivotal programs going to look like? Let's just maybe focus first on prevention. Obviously, healing, we don't even know. What is the regulatory path?

Dan Figa CEO

We will be speaking with the agency over time here. I think there's draft guidance that exists from four years ago, based on discussions that are six years old. And in that draft guidance, they're looking for co-primer endpoints of histology and PROs. It's a very high level, but also that guidance was directed towards healing. Yeah. It was unknown until I think these recent data sets that you can see a correlation to histological prevention of disease and prevention of symptoms. It hasn't been seen before. It really does open up, I think, from the FDA's perspective, I'm obviously not speaking for them here, that you can do both in one study in a prevention setting. There's nothing approved right now, but there is generally an acceptance that in histology, measuring VHCD is an adequate measure of histological improvement or performance. And on the PRO side, the CDSD that I referenced earlier, the tool, is a validated tool and I think it's been accepted by the field. So I think we're using the right instruments and endpoints, and it's really going to be a discussion of... When and how are you looking at the primary endpoints? Over six months, over one year? How are you administering gluten? You can't give a patient a gluten challenge for six straight months. So there's going to be discussion on exactly how to implement this, but these are very solvable. Solvable topics just going to require a discussion and presenting to the agency, and so that's what the next, you know, three, six, nine months is all about. And like I said, we publicly committed. I think we have enough assurance at this point that we will be able to start late-stage studies in 2027.

Got it. Maybe just a couple quick questions then. On EOE, how would you characterize a positive outcome there? Vitiligo, what is the plan there?

Dan Figa CEO

All right. So in EOE, we are running a 50-patient trial every other week, subcutaneous dosing over 12 weeks. So for approval, there's plenty of data out there. You need six months. So we're looking for a signal on symptoms, and we're looking for EOS reduction and EOS remissions. We'll be assessing all the normal endpoints. We are powered on the DSQ at 12 weeks to see a significant result.

Got it. Got it. Do we know if Novartis is going into EOE?

Dan Figa CEO

They have not announced it. It's already new. They're in three different derm inflame indications right now. Novartis has an IL-15 for reference.

Yeah, vitiligo. And we'll have more to say on vitiligo next year.

Dan Figa CEO

We're committed to starting that study in the first half of the year. It'll be a robust phase 2 study, and that's all I want to commit to right now.

Okay, I think I captured enough on this. I want to touch quickly on ANB101, BDCA2, how it is differentiated from the biogen molecule and how much of a read-through we should be expecting. I don't think you get any credit for that.

Dan Figa CEO

Yeah, I would agree with that right now. I think the investor focus is squarely on the CD122 program. So we... We licensed in the BDCA2 and retooled it preclinically a number of years ago. We've run a Phase 1a study. So I think we have a hypothesis. We validated the data preclinically, and now we've run the Phase 1a. And what we've observed is all consistent on the differentiation thesis, which is, I think, a holistically different PD profile than what Biogen's first-generation BDCA2 looks like, driven on two factors. One, a much longer half-life, and two, we are a depleter of plasmacytoid dendritic cells. That's where BDCA2 is expressed, on a rare immune cell that's present in selected immune diseases. So we're a depleter. I think Biogen's a non-depleting antagonist of that target. So those two factors are going to give us a different outcome profile, we believe, and again, validate in various different ways. So we're sitting on the phase 1a data. We do plan to present at a medical conference in 2027. Biogen is currently conducting three phase 3 studies, two that will read out in SLE in early December, or by the first half of December, and then an additional phase 3 trial in CLI. The results of both the SLE and the CLE trials will impact our path forward with our drug. So, you know, we're looking forward to seeing the face-to-results this year. We'll be making decisions in 2027 post the CLE results on exactly when and how we're moving forward with the program. But we do believe in the differentiation and excited. That's the second program in the portfolio.

Got it. Very good. And you mentioned the cash position. What is the bond rate or how good are you? How long?

Dan Figa CEO

We recently raised capital via Pipe last month off of our data, and we announced that we would be able to deliver the results of the initial late-stage celiac trial in the back half of 2029.

Got it. Perfect. Awesome. Very good. I think that's all I have for you. Thank you so much. Thank you.

Full-screen source Call document